Biohaven Pharmaceutical (BHVN)
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncolog...
- Open
- 14.075
- High
- 13.970
- Low
- 13.715
- Prev. Close
- 13.850
- Volume
- 138.05K
- Turnover
- 1.92M
- Avg Price
- 13.882
- Bid/Ask Ratio
- 66.67%
- Amplitude
- 1.84%
- 52wk High
- 18.566
- Volume Ratio
- 1.37
- Turnover Ratio
- 0.12%
Biohaven Pharmaceutical Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$23.0767.15%
Forecast & RatingBuy
17analysts
- Strong buy52.94%
- Buy23.53%
- Hold17.65%
- Sell0.00%
- Strong sell5.88%
News
- Simplywall · 18 hours ago
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?
- Market Beat · Aug 21 at 07:42 AM
HC Wainwright Decreases Earnings Estimates for Biohaven
- Market Beat · Aug 16 at 03:48 AM
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP
- Tip Ranks · Aug 12 at 12:15 PM
Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price Target
- Tip Ranks · Aug 12 at 01:45 AM
TD Cowen Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
- Tip Ranks · Aug 11 at 06:06 AM
Biohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price Target
